Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $566.8 million.

  • CureVac's Cash & Current Investments rose 2697.08% to $566.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $566.8 million, marking a year-over-year increase of 2697.08%. This contributed to the annual value of $518.7 million for FY2024, which is 1899.32% up from last year.
  • Per CureVac's latest filing, its Cash & Current Investments stood at $566.8 million for Q3 2025, which was up 2697.08% from $448.0 million recorded in Q2 2025.
  • In the past 5 years, CureVac's Cash & Current Investments ranged from a high of $1.6 billion in Q1 2021 and a low of $6.1 million during Q1 2022
  • Moreover, its 5-year median value for Cash & Current Investments was $510.7 million (2025), whereas its average is $538.2 million.
  • As far as peak fluctuations go, CureVac's Cash & Current Investments tumbled by 9961.48% in 2022, and later soared by 861319.62% in 2023.
  • CureVac's Cash & Current Investments (Quarter) stood at $933.6 million in 2021, then crashed by 45.33% to $510.4 million in 2022, then fell by 14.6% to $435.9 million in 2023, then increased by 18.99% to $518.7 million in 2024, then increased by 9.29% to $566.8 million in 2025.
  • Its Cash & Current Investments was $566.8 million in Q3 2025, compared to $448.0 million in Q2 2025 and $510.7 million in Q1 2025.